This article is more than 5 years old. Information may no longer be current.
Serum soluble Flt-1 may be biomarker for neovascular AMD
Click Here to Manage Email Alerts
Serum soluble Flt-1 may be a biomarker for the development of neovascular age-related macular degeneration, according to study findings.
Researchers analyzed 56 subjects without AMD, 53 subjects with early AMD and 97 subjects with neovascular AMD and measured serum soluble Flt-1 (sFlt-1) concentrations from each subject.
Mean serum sFlt-1 concentration was 90.8 pg/mL for non-AMD, 88.2 pg/mL for early AMD and 79.9 pg/mL for neovascular AMD. Neovascular AMD subjects had significantly decreased sFlt-1 compared with non-AMD and early AMD subjects (P < .01).
The odds of having neovascular AMD decreased by 27.8% based on each 10-point increase in sFlt-1.
Serum sFlt-1 less than 80 pg/mL among subjects older than 73 years was associated with a greater risk of neovascular AMD.
Disclosure: See the study for a full list of relevant financial disclosures.
Click Here to Manage Email Alerts